1. Report Overview
1.1 Leading Contract Manufacturing Organisations (CMOs) Overview
1.2 Benefits of This Report
1.3 How This Report Delivers Information
1.4 Main Questions This Report Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Related Reports
1.9 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2017
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2016
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2017-2027
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2017-2027
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2017-2027
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2017-2027
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2016?
3. Leading CMOs in North America
3.1 Catalent Pharma Solutions- the World’s Leading CMO
3.1.1 Catalent: Manufacturing Services and Capabilities
3.1.2 Divisional Segmentation – Breaking down Catalent’s Service
3.1.3 Catalent Pharma’s Revenue Growth, 2011-2016
3.1.4 Sustained Growth in Oral Products: Catalent Pharma’s Divisional Performance, 2011-2016
3.1.5 Catalent Is Expanding its Softgel Technologies Division
3.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
3.1.7 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
3.1.8 Adding New Early-Stage Development Services
3.1.9 Expansion in Japan – Growth Prospects for Catalent
3.1.10 New Business Contracts 2014-2016
3.1.11 Catalent New Products Launch
3.1.12 Catalent: Opportunities for Growth 2017-2027
3.1.13 Catalent: Mild Growth in Revenue, 2017-2027
3.2 Patheon – One of the Top 3 CMOs
3.2.1 Patheon – Global leader in Pharmaceutical Development Services
3.2.2 Contract Manufacturing Services at Patheon
3.2.3 Steady Revenue Growth 2011-2016
3.2.4 DPx Holdings: Developments
3.2.5 Adding New Formulations and Formulation Development Services
3.2.6 Expanding Services Through Acquisition, 2016
3.2.7 Patheon: SWOT Analysis 2017-2027
3.2.8 Patheon: Contract Manufacturing Revenue Forecast 2017-2027
3.3 Baxter BioPharma Solutions
3.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
3.3.2 Historic Revenue Performance 2011-2016
3.3.3 Baxter BioPharma SWOT Analysis 2017-2027
3.3.4 Baxter BioPharma Revenue Forecast 2017-2027
3.3.5 Reassessing Manufacturing Capacity
3.4 AbbVie Contract Manufacturing
3.4.1 AbbVie Offers Full-Service Contract Manufacturing
3.4.2 Expanding and Adding New Services: 2013-2014
3.4.3 AbbVie Contract Manufacturing: Revenue 2011-2016
3.4.4 Biologics and HPAPIs Are an Opportunity for Growth 2017-2027
3.4.5 AbbVie Contract Manufacturing Revenue Forecast 2017-2027
3.5 Pfizer CentreOne
3.5.1 Pfizer CentreSource: Historic Revenue Performance, 2011-2016
3.5.2 Will Hospira Acquisition Lead to Revenue Growth in Future?
3.5.3 Outlook for CentreOne: Revenue Forecast 2017-2027
4. Leading European Contract Manufacturing Organisations
4.1 Lonza
4.1.1 Lonza Is a Leader in Biologics Manufacturing
4.1.2 Lonza Contract Manufacturing and Development: 2011-2016
4.1.3 Investing in Advanced Biological Drug Sectors
4.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
4.1.5 The Regenerative Medicine Future in Japan
4.1.6 Lonza: SWOT Analysis 2017-2027
4.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2017-2027
4.2 Evonik Degussa
4.2.1 Investing in API and Drug Delivery Services
4.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2011-2016
4.2.3 Evonik Is a HPAPI Specialist
4.2.4 Evonik Continues to Grow Across All Segments
4.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
4.2.6 Evonik Degussa: Revenue Forecast 2017-2027
4.3 Royal DSM
4.3.1 Amplified Revenue Growth in Pharma Manufacturing 2011-2016
4.3.2 DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services 2011-2016
4.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
4.3.4 DPx Holdings: A New Pharma Leader
4.3.5 Investing in Biopharma Manufacturing
4.3.6 Expanding API Manufacturing
4.3.7 Generics and Biologics Are an Opportunity for Growth, 2017-2027
4.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2017-2027
4.4 Boehringer Ingelheim Contract Manufacturing
4.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
4.4.2 Production Through to Fill and Finished Biopharmaceuticals
4.4.3 A Track Record of Production for 29 Biopharma Products
4.4.4 Increasing Revenue from Contract Manufacturing, 2011-2016
4.4.5 Pulling Out of Small Molecule API Manufacturing
4.4.6 Expanding through New Services
4.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2017-2027
4.4.8 Boehringer Ingelheim: Revenue Forecast 2017-2027
4.5 Fareva
4.5.1 Fareva Has 35 Years’ Manufacturing Experience
4.5.2 Revenue Growth through Acquisitions: 2011-2016
4.5.3 Fareva SWOT Analysis: 2017-2027
4.5.4 Fareva Revenue Forecast: 2017-2027
4.6 Aenova Group
4.6.1 Acquisition of Haupt Creates European CMO Giant
4.6.2 Aenova’s Ever Expanding Manufacturing Capacity
4.6.3 Aenova’s Revenue 2011-2016: Organic Growth and Acquisitions
4.6.4 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2016
4.6.5 Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2017-2027
4.7 Famar
4.7.1 Famar Is an Expert in Lyophilisation
4.7.2 Sustained Growth in Famar’s Revenue: 2011-2016
4.7.3 Expanding Outside Europe
4.7.4 Further Site Acquisitions Are an Opportunity for Growth 2017-2027
4.7.5 How Will Famar Perform 2017-2027?
4.8 Vetter Pharmaceutical
4.8.1 Vetter is an Injectable Manufacturing Specialist
4.8.2 Rapidly Growing Revenue in the US and Germany: 2011-2016
4.8.3 Services, Collaborations and Differentiating Factors
4.8.4 Expanding Services in US and Asia
4.8.5 Biologics Are an Opportunity for Growth for Vetter 2017-2027
4.8.6 Vetter Outlook: Revenue Forecast 2017-2027
4.9 Almac Group
4.9.1 Almac’s Manufacturing Services
4.9.2 Almac Outpaces the Market: 2011-2016
4.9.3 Almac Adding Capacity Globally
4.9.4 New Services Added 2012-2016
4.9.5 Almac Group: Contract Manufacturing Market Outlook 2017-2027
4.9.6 How Will Almac Group Perform 2017-2027?
4.10 Delpharm
4.10.1 Finished Dosage Form Manufacturing for Developed Markets
4.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2011-2016
4.10.3 Delpharm: Outlook and Prospects for Growth 2017-2027
4.10.4 Generics Will Drive Revenue Growth for Delpharm 2017-2027
4.11 Siegfried
4.11.1 Siegfried’s Acquisitions, 2011-2016
4.11.2 Expanding Siegfried’s Manufacturing Footprint Globally
4.11.3 Expanding High Potency API Capabilities
4.11.4 Siegfried: Financial Performance 2011-2016
4.11.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis 2016
4.11.6 Continued Revenue Growth for Siegfried 2017-2027
4.12 Corden Pharmaceutical
4.12.1 CordenPharma Service Division
4.12.2 CordenPharma Emerging in the API Market
4.12.3 Investments in Highly Potent Capabilities
4.12.4 CordenPharma: SWOT Analysis 2017-2027
4.13 Recipharm
4.13.1 Contract Development and Manufacturing Services
4.13.2 Recipharm: Financial Performance 2011-2016
4.13.3 Recipharm Invests in Facility Expansion
4.13.4 Recipharm Growing in the Development and Technology Market Through Acquisitions
4.13.5 Recipharm: Opportunities for Growth 2017-2027
4.13.6 Outlook for Recipharm: Revenue Forecast 2017-2027
4.14 Aesica Pharmaceuticals
4.14.1 Aesica Manufactures APIs and Finished Dosage Forms
4.14.2 Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2011-2016
4.14.3 Partnering with Academia for Innovative Solutions
4.14.4 Growth through Acquisitions and Internal Expansion
4.14.5 Aesica: Opportunities for Expansion 2017-2027
4.14.6 Forecast Aesica Financial Performance, 2017-2027
5. Leading Japanese Pharma Contract Manufacturing Organisations
5.1 Nipro Corporation: Japan’s Leading CMO
5.1.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
5.1.2 Nipro: Decline in Revenue But increasing Operating Profits 2011-2016
5.1.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2017-2027
5.1.4 Nipro Revenue and Profitability Forecast 2017-2027
5.2 Daito Pharmaceutical
5.2.1 Daito Has a Portfolio of More than 30 APIs
5.2.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2011-2016
5.2.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2017-2027
5.2.4 Sustained Growth in Revenue and Operating Profit for Daito, 2017-2027
6. Leading Developed-Market API Specialists
6.1 Teva API
6.1.1 API Manufacturing Services
6.1.2 Teva API: Financial Performance 2011-2016
6.1.3 Building a Footprint in Mexico, India and China
6.1.4 Teva API: SWOT Analysis 2017-2027
6.1.5 Outlook for Teva API: Revenue Forecast 2017-2027
6.2 Esteve Química
6.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
6.2.2 Expanding in the US, 2016
6.2.3 Esteve Química: SWOT Analysis 2017-2027
6.3 Euticals
6.3.1 Euticals Manufactures More than 200 APIs
6.3.2 Acquisitions Drive Growth 2011-2016
6.3.3 Adding Capacity for Finished Dosage Forms
6.3.4 Asian Expansion Is an Opportunity for Growth 2017-2027
6.3.5 Euticals: Revenue Forecast 2017-2027
7. Leading Chinese Pharma Contract Manufacturers
7.1 Zhejiang Hisun Pharmaceutical
7.1.1 API Manufacturing for Markets Worldwide
7.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2011-2016
7.1.3 Moving into International Drug Marketing
7.1.4 Zhejiang Hisun: Opportunities for Growth 2017-2027
7.1.5 Zhejiang Hisun: Strong API Revenue Growth 2017-2027
7.2 Zhejiang Huahai Pharmaceuticals
7.2.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
7.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2011-2016
7.2.3 Expanding in the US Generic Drugs Market
7.2.4 Zhejiang Huahai: SWOT Analysis, 2017-2027
7.2.5 Zhejiang Huahai: Revenue Forecast, 2017-2027
7.3 Shandong Xinhua Pharmaceutical
7.3.1 Experience in APIs and Finished Dosage Forms
7.3.2 Shandong Xinhua: Strong Revenue Growth 2011-2016
7.3.3 Growing through Joint Ventures
7.3.4 Looking to Expand in the US and EU 2017-2027
7.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2017-2027
8. Leading Indian Pharmaceutical Contract Manufacturers
8.1 Aurobindo Pharma
8.1.1 API Manufacturing Services
8.1.2 Aurobindo Pharma: Steady Revenue Growth 2011-2016
8.1.3 Aurobindo Expanding Outside of Antibacterials
8.1.4 Aurobindo: Opportunities for Expansion 2017-2027
8.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2017-2027?
8.2 Divis Laboratories
8.2.1 Divis Laboratories and the Contract Manufacturing Industry
8.2.2 Divis Laboratories: A Rapidly Growing CMO, 2011-2016
8.2.3 Divis Laboratories: API Manufacturing Outlook 2017-2027
8.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2017-2027
8.3 Dr. Reddy’s Laboratories
8.3.1 API and FDF Manufacturing Services
8.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2011-2016
8.3.3 Advancing in Complex Drug Manufacturing
8.3.4 Expanding in the European Manufacturing Market
8.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2017-2027
9. Conclusions of the Study
9.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
9.2 Strategies for Growth: Prospects for Leading CMOs, 2017-2027
9.3 High Demand for Biopharmaceutical Manufacturing Services
9.4 Investing in Novel Technologies
9.5 Outlook for API Manufacturers
Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Table
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2017
Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2014-2016
Table 2.3 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2016
Table 2.4 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2016
Table 2.5 Contract Manufacturing Market Forecast by Service: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2021 and 2027
Table 2.6 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2016
Table 3.1 Catalent Details, 2016
Table 3.2 Catalent Facility Details, 2016
Table 3.3 Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
Table 3.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2016
Table 3.5 Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2011-2016
Table 3.6 Catalent New Products Launch: New Products, Annual growth (%), CAGR (%), 2012-2016
Table 3.7 Catalent Pharma SWOT Analysis, 2017
Table 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
Table 3.9 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2021-2027
Table 3.10 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
Table 3.11 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 3.12 Patheon Details, 2016
Table 3.13 Patheon Manufacturing Facilities, 2017
Table 3.14 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 3.15 Patheon: SWOT Analysis, 2016
Table 3.16 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 3.17 Baxter BioPharma Solutions Details, 2016
Table 3.18 Baxter BioPharma Solutions: Facilities and Services Offered, 2016
Table 3.19 Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 3.20 Baxter BioPharma Solutions SWOT Analysis, 2016
Table 3.21 Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 3.22 AbbVie Contract Manufacturing: Details, 2016
Table 3.23 AbbVie Contract Manufacturing Facility Capabilities, 2016
Table 3.24 AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), 2011-2016
Table 3.25 AbbVie Contract Manufacturing SWOT Analysis, 2016
Table 3.26 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 3.27 Pfizer CentreOne Details, 2016
Table 3.28 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 3.29 Pfizer CentreOne SWOT Analysis, 2016
Table 3.30 Forecast Pfizer CentreOne Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 4.1 Lonza Details, 2016
Table 4.2 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
Table 4.3 Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2011-2016
Table 4.4 ADCs Approved and in Late Stage Clinical Development, 2014
Table 4.5 Lonza SWOT Analysis, 2016
Table 4.6 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2016-2021
Table 4.7 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2022-2027
Table 4.8 Evonik Degussa Details, 2016
Table 4.9 Evonik Health and Nutrition: R&D and Production Sites by Region, 2016
Table 4.10 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 4.11 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2016
Table 4.12 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.13 Royal DSM Details, 2016
Table 4.14 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2011-2016
Table 4.15 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 4.16 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 4.17 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2016
Table 4.18 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
Table 4.19 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2022-2027
Table 4.20 Boehringer Ingelheim Biopharmaceuticals Details, 2016
Table 4.21 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
Table 4.22 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 4.23 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 4.24 Boehringer Ingelheim: SWOT Analysis, 2016
Table 4.25 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.26 Fareva Details, 2016
Table 4.27 Fareva Manufacturing Facilities, 2016
Table 4.28 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 4.29 Fareva: SWOT Analysis, 2016
Table 4.30 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.31 Aenova Group Details, 2016
Table 4.32 Aenova Group Manufacturing Capacity by Dosage Form, 2016
Table 4.33 Aenova Group Manufacturing Facility Details, 2016
Table 4.34 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
Table 4.35 Aenova Group SWOT Analysis, 2016
Table 4.36 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2016-2021
Table 4.37 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
Table 4.38 Famar Details, 2016
Table 4.39 Famar Pharmaceutical Manufacturing Facilities, 2016
Table 4.40 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 4.41 Famar: SWOT Analysis, 2016
Table 4.42 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.43 Vetter Details, 2016
Table 4.44 Vetter Pharmaceutical Facilities, 2016
Table 4.45 Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 4.46 Vetter: SWOT Analysis, 2016
Table 4.47 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.48 Almac Details, 2016
Table 4.49 Almac Pharmaceutical Manufacturing Facilities Details, 2016
Table 4.50 Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 4.51 Almac: SWOT Analysis, 2016
Table 4.52 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2016-2021
Table 4.53 Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
Table 4.54 Delpharm Details, 2016
Table 4.55 Delpharm: Facilities and Services, 2016
Table 4.56 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 4.57 Delpharm: SWOT Analysis, 2016
Table 4.58 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
Table 4.59 Siegfried Details, 2016
Table 4.60 Siegfried Pharmaceutical Manufacturing Facilities Details, 2016
Table 4.61 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 4.62 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 4.63 Siegfried: SWOT Analysis, 2016
Table 4.64 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2016-2021
Table 4.65 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2022-2027
Table 4.66 CordenPharma Details, 2016
Table 4.67 CordenPharma Facilities and Service Details, 2016
Table 4.68 Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 4.69 Corden Pharmaceuticals SWOT Analysis, 2016
Table 4.70 Recipharm Details, 2016
Table 4.71 Recipharm: Facility Details and Services, 2016
Table 4.72 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 4.73 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2016
Table 4.74 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2016
Table 4.75 Recipharm: SWOT Analysis, 2016
Table 4.76 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
Table 4.77 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
Table 4.78 Aesica Details, 2016
Table 4.79 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
Table 4.80 Aesica SWOT Analysis, 2016
Table 4.81 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
Table 4.82 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
Table 5.1 Nipro Pharma Details, 2016
Table 5.2 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2011-2016
Table 5.3 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2016
Table 5.4 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
Table 5.5 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2016
Table 5.6 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
Table 5.7 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 5.8 Daito Pharmaceuticals: Details, 2016
Table 5.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
Table 5.10 Daito Pharmaceuticals SWOT Analysis, 2016
Table 5.11 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
Table 5.12 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 6.1 Teva API Details, 2016
Table 6.2 Teva API: Site Acquisitions, 1980- 2011
Table 6.3 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 6.4 Teva API SWOT Analysis, 2016
Table 6.5 Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 6.6 Esteve Química Details, 2016
Table 6.7 Esteve Química SWOT Analysis, 2016
Table 6.8 Euticals Details, 2016
Table 6.9 Euticals Facility Details: Production Capacity (m3) and Key Products, 2016
Table 6.10 Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2016
Table 6.11 Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 6.12 Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2016
Table 6.13 Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2016
Table 6.14 Euticals SWOT Analysis, 2016
Table 6.15 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 7.1 Zhejiang Hisun Pharmaceuticals Details, 2016
Table 7.2 Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 7.3 Zhejiang Hisun Manufacturing: SWOT Analysis, 2016
Table 7.4 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 7.5 Zhejiang Huahai Pharmaceuticals Details, 2016
Table 7.6 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 7.7 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2016
Table 7.8 Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 7.9 Shandong Xinhua Pharmaceuticals Details, 2016
Table 7.10 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2016
Table 7.11 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 7.12 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2016
Table 7.13 Shandong Xinhua Manufacturing: SWOT Analysis, 2016
Table 7.14 Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 8.1 Aurobindo Pharma Details, 2016
Table 8.2 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 8.3 Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
Table 8.4 Aurobindo Contract Manufacturing: SWOT Analysis, 2016
Table 8.5 Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 8.6 Divis Laboratories Details, 2016
Table 8.7 Divis Laboratories: Facility Details, Production Capacity and Services, 2016
Table 8.8 Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 8.9 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2016
Table 8.10 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2016
Table 8.11 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2016
Table 8.12 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
Table 8.13 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 8.14 Dr. Reddy’s Laboratories Details, 2016
Table 8.15 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
Table 8.16 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 8.17 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2016
Table 8.18 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2016
Table 8.19 Dr. Reddy’s Laboratories: SWOT Analysis, 2016
Table 8.20 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Table 9.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 9.2 CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2011-2016
Table 9.3 Leading CMOs: Combined Annual Revenue ($m), Annual Growth (%), Market Share (%), CAGR (%), 2016-2027
Table 9.5 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2015-2020
Table 9.6 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2021-2027
List of Figures
Figure 1.1 Segmentation of Contract Manufacturing Organisations, 2017
Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2017
Figure 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2014-2016
Figure 2.3 Contract Manufacturing Market by Service: Market Share (%), 2016
Figure 2.4 Contract Manufacturing Market by Leading Country: Market Share (%), 2016
Figure 2.5 Contract Manufacturing Market Forecast by Service: Market Size ($bn), 2016, 2021 and 2027
Figure 2.6 Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2017-2027
Figure 3.1 Catalent Facilities by Region, 2016
Figure 3.2 Catalent Facilities by Service Offered, 2016
Figure 3.3 Catalent Financial Performance: Revenue ($m), 2011-2016
Figure 3.4 Catalent Financial Performance by Product Type: Revenue Share (%), 2016
Figure 3.5 Catalent Financial Performance by Division: Revenue ($m), 2011-2016
Figure 3.6 Catalent New Products Launch: New products, 2012-2016
Figure 3.7 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
Figure 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
Figure 3.9 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2016-2027
Figure 3.10 Patheon Pharmaceutical Development Projects (%) by Phase, 2016
Figure 3.11 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2016
Figure 3.12 Patheon Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 3.13 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 3.14 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
Figure 3.15 Baxter BioPharma Manufacturing: Revenue ($m), 2011-2016
Figure 3.16 Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2016-2027
Figure 3.17 AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2016
Figure 3.18 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 3.19 Pfizer CentreOne: Revenue ($m), 2011-2016
Figure 3.20 Forecast Pfizer CentreOne Manufacturing: Revenue ($m), 2016-2027
Figure 4.1 Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
Figure 4.2 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2016
Figure 4.3 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 4.4 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 4.5 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2016
Figure 4.6 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.7 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.8 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.9 DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2011-2016
Figure 4.10 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2011-2016
Figure 4.11 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
Figure 4.12 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.13 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.14 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.15 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.16 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.17 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.18 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
Figure 4.19 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
Figure 4.20 Famar Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.21 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.22 Vetter Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.23 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.24 Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 4.25 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
Figure 4.26 Forecast Almac Pharmaceuticals: Revenue ($m), 2022-2027
Figure 4.27 Delpharm: Revenue ($m), 2011-2016
Figure 4.28 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 4.29 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
Figure 4.30 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2011-2016
Figure 4.31 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2015
Figure 4.32 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2016
Figure 4.33 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 4.34 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 4.35 Corden Pharmaceuticals: Revenue ($m), 2011-2016
Figure 4.36 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
Figure 4.37 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2016
Figure 4.38 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2016
Figure 4.39 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 4.40 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 4.41 Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2011-2016
Figure 4.42 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 4.43 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 5.1 Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2011-2016
Figure 5.2 Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
Figure 5.3 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 5.4 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 5.5 Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2011-2016
Figure 5.6 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
Figure 5.7 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
Figure 6.1 Teva API: Revenue ($m), 2011-2016
Figure 6.2 Forecast Teva API Manufacturing: Revenue ($m), 2016-2027
Figure 6.3 Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2016
Figure 6.4 Euticals: Revenue ($m), 2011-2016
Figure 6.5 Euticals Revenue by Product Class: Share of Total Revenues (%), 2016
Figure 6.6 Euticals Revenue by Region: Share of Total Revenues (%), 2016
Figure 6.7 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
Figure 7.1 Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2011-2016
Figure 7.2 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2016-2027
Figure 7.3 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2011-2016
Figure 7.4 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2016-2027
Figure 7.5 Shandong Xinhua: Revenue ($m), 2011-2016
Figure 7.6 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2016
Figure 7.7 Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2016-2027
Figure 8.1 Aurobindo Contract Manufacturing: Revenue ($m), 2011-2016
Figure 8.2 Aurobindo Contract Manufacturing: Revenue Share (%), 2014
Figure 8.3 Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2016-2027
Figure 8.4 Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2011-2016
Figure 8.5 Divis Laboratories Revenue Distribution: Revenue ($m), 2016
Figure 8.6 Divis Laboratories Revenue by Region: Share of Total (%), 2016
Figure 8.7 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2016-2021
Figure 8.8 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2022-2027
Figure 8.9 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2016
Figure 8.10 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2011-2016
Figure 8.11 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2015
Figure 8.12 Dr. Reddy’s Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2016
Figure 8.13 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2016-2027
Figure 9.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2011-2016
Figure 9.2 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2011-2016
Figure 9.3 Leading CMOs: Combined Annual Revenue ($bn), 2016-2027
Table 9.4 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
Figure 9.4 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2016-2027
Figure 9.5 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2015-2020
Figure 9.6 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2021-2027
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
